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A B S T R A C T
Aim of this study was to estimate efficacy of gemcitabine in first and the second-line chemotherapy for patients with
advanced non-small cell lung cancer (stage III and IV). In first-line chemotherapy, 120 patients were treated with dif-
ferent chemotherapy regimens. Fifty-nine patients were treated with gemcitabine/cisplatin (PG), 41 with cisplatin/
etoposide (PE) and 20 with mitomycin/ifosfamide/cisplatin (MIC). Forty patients, unsuccessfully treated with PE and
MIC in first-line therapy were treated with PG (24 pts) and with best supportive care (BSC) (16 pts). In first-line ther-
apy PG was superior to PE and MIC protocol (mean survival (MS) 10 vs. 7 vs. 8.5 months). Response rate (RR) for PG
in first-line therapy was 46% and 21% in second-line. We showed also significantly better survival in patients treated
with PG in second-line chemotherapy comparing to best supportive care (MS 9 vs. 5.5 months). Toxic side effects for
combination PG was acceptable. This study confirmed that PG combination is safe and effective as first and sec-
ond-line chemotherapy for patients with advanced non-small cell lung cancer.
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Introduction
Lung cancer is a leading cause of death out of all carci-
nomas in the world. Non-small cell carcinoma (NSCLC)
presents 80% of all cases of lung cancers1. At the time of
diagnosis, majority of patients have locally advanced or
metastatic disease (stages III B and IV). At the moment
of diagnosis only third of patients are candidates for
radical surgery. However, more than 50% of patients
who underwent radical surgery will have relapse of
cancer2. Summarizing these data, around 80% of pa-
tients with lung cancer are candidates for chemother-
apy. A large number of patients on one hand and poor
survival rate of patients on chemotherapy on the other
hand make chemotherapy of small cell lung cancer very
challenging. Because of that, many basic investigations
and clinical studies have been conducted, including
studies of new, third-line drugs for chemotherapy. Plati-
num based protocols are used for years showing a signif-
icant advantage in survival as compared with best sup-
portive care3. According to meta-analysis, platinum
based protocols decreased mortality by 27%, increased
1-year survival time by 10%, and increased survival for
two months as compared with best supportive care.
However, an average survival reached a Plato, and
rarely exceeds 10 months. Majority of patients die
within two years after diagnosis4–7. In the past ten
years, many new drugs in different classes have been
discovered and introduced to the clinical practice. For
most of them, like paclitaxel, docetaxel, vinorelbine and
gemcitabine, intensive clinical trials have been done.
Our studies showed that those drugs were more effec-
tive in combination than as a monotherapy. With combi-
nation therapy response rate increased two times, sur-
vival time was longer for 2 months and one-year
survival increased by 5%8–9. Most of the new drugs were
also investigated in second-line chemotherapy in pa-
tients with no response to first-line chemotherapy and
in patients with a relapse of cancer after first-line
chemotherapy10,11.
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Gemcitabine is analogous to nucleoside (2’,2’-difu-
orodeoxycytidine), which stops DNA transcription and
synthesis by implanting itself in DNA double helix12.
Gemcitabine can be used as a monotherapy in treat-
ment of NSCLC, but more often it is used in combina-
tion with cisplatin or carboplatin, due to synergistic ef-
fects of these two drugs13.
The aim of this study was to estimate efficacy of
gemcitabine in combination with cisplatin in first and
second-line chemotherapy in Croatian patients with ad-
vanced non-small cell lung cancer (stages III A-N2, III B
and IV).
Patients and Methods
We retrospectively analysed 120 patients (84 male
and 36 female) treated at the University Hospital for
Lung Diseases »Jordanovac« with gemcitabine in first
and second-line chemotherapy during 2001 and 2002.
Patients was classified according to cytological tumor
type to: adenocarcinoma (73 pts), squamous cell carci-
noma (planocellular carcinoma) (20 pts), large-cell carci-
noma (7 pts), adeno-planocellular carcinoma (11 pts),
non-differentiated carcinoma (9 pts); as stage IIIA-N2
(16 pts), stage IIIB (57 pts), stage IV (47 pts) and with
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 (21 pts), 1 (62 pts) and 2 (37 pts). We
compared results of gemcitabine in combination with
cisplatin (59 pts) with standard chemotherapy protocols
usually used in the first-line chemotherapy in our hospi-
tal. Standard chemotherapy protocols include combina-
tion of cisplatin and etoposide (PE protocol) (41 pts) and
combination of mitomycin, ifosfamide and cisplatin
(MIC protocol) (20 pts). All patients unsuccessfully
treated with PE and MIC protocols in first line (40 pts)
were candidates for second line chemotherapy with
gemcitabine. Efficacy and safety of gemcitabine and
cisplatin in second line chemotherapy were analysed in
group of patients who accepted second line chemother-
apy (24 pts) and compared with patients treated only
with best supportive care who refused this chemother-
apy (16 pts).
Efficacy of chemotherapy was estimated by deter-
mine the percentage of patients with complete response
(CR): disappearance of all tumor lesions, partial re-
sponse (PR): regression more then 50% of tumor lesions,
stable disease (SD): regression less then 50% or without
progression of tumor lesions and disease progression
(PD): progression during chemotherapy. We also ana-
lysed time to progression of disease (TTP): interval from
the initiation of chemotherapy to disease progression,
mean survival, and percentage of patients with one and
two year survival. Toxicities were assessed at the end of
every cycle using Worl Health Organisation (WHO) rec-
ommendations for grading of acute and subacute toxic-
ity (grade 0–4).
Survival curves were calculated according to the
method of Kaplan and Meier. Statistical probability
(p-value) was calculated using Gehan-Wilcox test14.
Chemotherapy protocols and dosage used in this
study: 1. PE protocol: cisplatin 80 mg/m2 on day 1 and
etoposide 120 mg/m2 on day 1, and 100 mg/m2 on days 2
and 3; 2. MIC protocol: mitomycin 6 mg/m2 and ifos-
famide 3 g/m2 and cisplatin 70 mg/m2; 3. PG protocol:
cisplatin 80 mg/m2 on day 1 and gemcitabine 1250
mg/m2 on day 1 and 8.
All protocols were applied every three weeks with an
average number of cycles four.
Results
Our study included a total of 120 patients (84 males
and 36 females), with an average age of 59 years (range
from 41 to 78 years) and with cytological proven non-
-small cell lung carcinoma that were treated by chemo-
therapy. Most of the patients had adenocarcinoma (73
pts – 60%). Majority of patients were classified as stages
III B and IV (104 pts – 87%) and only 16 patients – 13%
were in stage III A-N2. A criterion for inclusion was
ECOG performance status 0, 1 and 2. Of all analysed
patients 59 were treated with gemcitabine and cis-
platin, 41 with PE protocol and 20 patients with MIC
protocol as first line chemotherapy. In 40 out of 61 pa-
tients, who were treated with standard protocols (PE
and MIC protocols), there was a poor response. In 24 pa-
tients with poor response, second-line chemotherapy
was applied according to gemcitabine and cisplatin pro-
tocol. Other 16 patients with poor response were treated
with best supportive care (BSC) because they refused
chemotherapy. In total, 12 patients were lost in the fol-
low up (Table 1).
















Male 84 41 29 14 15 11
Female 36 18 12 6 9 5
Cytological tumor type
Adeno 73 35 20 18 7 8
Plano 20 9 9 2 9 2
Macro 7 5 2 0 1 2
Adeno-plano 11 6 5 0 2 3
Nondifferentiated 9 4 5 0 5 1
Stage
IIIA-N2 16 8 3 5 2 0
IIIB 57 28 14 15 18 2
IV 47 23 24 0 4 14
Performance status
0 21 10 5 6 9 0
1 62 31 19 12 13 3
2 37 18 17 2 2 13
PG – cisplatin + gemcitabine, PE – cisplatin + etoposide, MIC –
mitomycin + ifosfamide + cisplatin
In first-line chemotherapy, response rate was signifi-
cantly better in patients treated with PG protocol when
compared with PE and MIC protocol, 46% vs. 12% and
25% respectively. Median survival also proved to be
better in patients treated with PG protocol than in pa-
tients treated with PE and MIC protocol, 10 month vs. 7
and 8.5 months. One-year survival was significantly
better in patients treated with PG protocol than in pa-
tients treated with PE and MIC protocol, 37% vs. 23%
and 30%. Two-year survival was 7% in patients treated
with PG protocol. No patients treated with standard
protocols survived 2 years. One year-survival in pa-
tients treated with PG protocol as second-line chemo-
therapy was 17%. These were patients who were treated
with standard protocols (PE and MIC protocols) in first-
-line chemotherapy. Median survival of patients treated
with PG protocol as second-line chemotherapy was 9
months vs. 5.5 months in group of patients treated only
with best supportive care (Table 2).
The overall toxicity profile for all combinations of
drugs was similar. PG produced less grade 3 and 4 alo-
pecia and neutropenia but more grade 3 and 4 throm-
bocytopenia than did PE and MIC. Nausea and vomit-
ing were reported more frequently in the gemcitabine
arm than in PE and MIC (Table 3). Changes of skin and
neurological toxicity were not significant in any schedule.




Response PG 1st line PE MIC PG 2nd line BSC in 2nd line
CR 3 (5%) 0 1 (5%) 0
PR 24 (40%) 5 (12%) 4 (20%) 5 (21%) NA
RR (CR+PR) 27 (46%) 5 (12%) 5 (25%) 5 (21%)
SD 28 (47%) 10 (24%) 5 (25%) 16 (67%)
PD 4 (7%) 26 (64%) 10 (50%) 3 (12%)
TTPD (median, range) 6 months (2–19) 4 months (2–8) 5 months (2–9) 5 months (3–9) 3 months (2–5)
MS (median, range) 10 months (3–25) 7 months (2–17) 8.5 months (6–17) 9 months (5–17) 5.5 months (4–12)
PG – cisplatin + gemcitabine, PE – cisplatin + etopiside, MIC – mitomycin + ifosfamide + cisplatin, CR – complete response, PR –
partial response, RR – response rate, MR – minimum response, SB – stable disease, PD – disease progression, TTPD – time to dis-
ease progression, MS – mean survival, NA – not applicable
TABLE 3
TOXIC SIDE EFFECTS OF 3rd AND 4th DEGREE (ITS CLASSIFI-
CATION) FOR CISTPALTIN/GEMCITABINE PROTOCOL
PG PE MIC
Neutropenia 22 (27%) 14 (34%) 8 (40%)
Thrombocytopenia 21 (35%) 7 (17%) 3 (15%)
Nausea and vomiting 17 (21%) 7 (17%) 3 (15%)
Alopecia 8 (13%) 16 (39%) 8 (40%)
Changes on skin 1 (1%) 0 (0%) 0 (0%)
Neurological 1 (1%) 2 (5%) 1 (5%)
PG – cisplatin + gemcitabine, PE – cisplatin + etoposide, MIC –
mitomycin + ifosfamide + cisplatin














































Fig. 1. Survival curves of patients treated in first-line chemotherapy with PG and PE:
PG – gemcitabine/cisplatin, PE – cisplatin/etoposide.
PG schedule offers a slightly better survival com-
pared to standard chemotherapy setting (PE and MIC
protocols) in first-line chemotherapy (Figures 1 and 2)
and compared to BSC in second line setting (Figure 3).
Discussion
Results of this study showed that combination of
cisplatin and gemcitabine is superior to standard proto-
cols (PE and MIC protocols) in first-line chemotherapy
of advanced non-small cell lung cancer. Many studies
have compared cisplatin and gemcitabine with other
standard protocols for first-line chemotherapy. Differ-
ences in the results of these studies can be explained by
different inclusion criteria and different parameters
used to estimate treatment efficacy. Cardenal et al15
found no statistically significant difference in mean sur-
vival in patients treated with cisplatin and gemcitabine
as compared to the patients treated with cisplatin and
etoposide (8.7 vs. 7.2 months). In a large study by ECOG
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Fig. 2. Survival curves of patients treated in the first-line chemotherapy with PG and MIC:















































Fig. 3. Survival curves of patients treated in the second-line therapy with PG and BSC: PG – gemcitabine/cisplatin, BSC – best
supportive care.
1954, various combinations of platinum based drugs
with paclitaxel, docetaxel and gemcitabine were com-
pared. The results of that study showed no significant
difference in survival, which was approximately 8
months16. Phase III study was conducted in 372 pa-
tients with stages III and IV non-small cell lung cancer
who were not previously treated. It showed no benefit of
carboplatin and gemcitabine as compared with combi-
nations of mitomycin, ifosfamide and cisplatin and mi-
tomycin, vinblastin and cisplatin. Mean survival was
little over 7 months17. However, some studies showed
significant benefit of cisplatin and gemcitabine in pa-
tients with advanced NSCLC as compared to standard
protocols18. Crino et al. showed that patients treated
with cisplatin and gemcitabine had response rate of
40.6% with mean survival of 13.5 months19. Our pa-
tients treated with combination of cisplatin and gem-
citabine had response rate of 45% and mean survival of
10 months. Our results are in the middle of those two
groups of studies which compared cisplatin and gem-
citabin with other protocols. We showed a statistically
significant improvement in survival (p=0.064) in the pa-
tients treated with PG protocol as compared with pa-
tients treated with PE and MIC protocols. Analyzing
Kaplan-Meier’s curve, we showed the greatest differ-
ence in survival. Survival was longer for more than 7
months in patients treated with PG protocol. Our re-
sults are in favor of study of Le Chevalier et al. which
showed reduction of mortality by 3.9% per year in pa-
tients treated with gemcitabine based protocols as com-
pared with non-gemcitabine protocols20.
Our analysis of various agents in second-line chemo-
therapy showed that the best results were obtained in
patients treated with docetaxel in second-line chemo-
therapy, for those patients who had a poor response on
first-line chemotherapy, and in patients with relapse of
disease after successful first-line chemotherapy. Doce-
taxel, as monotherapy in second–line chemotherapy in
patients with unsuccessful first–line chemotherapy im-
proved survival to 7.5 months with 1-year survival by
37%. These results are significantly better than in pa-
tients treated with best supportive care or combination
of vinorelbine and ifosfamide21. Wachters et al. showed
similar results in patients treated with docetaxel and
carboplatin in second-line chemotherapy of advanced
NSCLC22. Based on mentioned studies docetaxel is stan-
dard for second-line chemotherapy of advanced NSCLC.
Investigations on gemcitabine in second-line chemo-
therapy of advanced NSCLC are rare although the first
results of its application in second-line therapy turned
to be promising23. Studies of gemcitabine as second-line
agent showed a significant efficacy with reasonable tox-
icity. Studies showed that patients with stages III and
IV NSCLS treated with gemcitabine monotherapy in
second-line chemotherapy had response rate approxi-
mately 20% with mean survival of 7 months and 1-year
survival by 22%24–26. Combinations of gemcitabine with
new generation of drugs showed better results than
gemcitabine alone. Gemcitabine in combination with
irinotecan had mean survival of 8.1 months with 1-year
survival by 36%27. Combination with gemcitabine shoved
similar results (8.3 months and 34.3%)28. Best results are
achieved with combination of gemcitabine and docetaxel
(mean survival of 11.1 months, and response rate of
41%) with mild toxic, mostly hematological side-ef-
fects29. In our study, the patients treated with cisplatin
and gemcitabine combination in second-line chemother-
apy had median survival of 9 month and with response
rate of 17%. These results are similar to gemcitabine
and irinotecan or vinorelbine combination. Comparing
our results with results of studies of gemcitabine and
docetaxel combination, we can conclude that combina-
tion of gemcitabine and docetaxel is superior to cisplatin
and docetaxel in second-line chemotherapy. Toxic side-
-effects were similar in all studies.
This study confirmed that cisplatin and gemcitabine
combination is safe and effective combination for treat-
ing patients with advanced non-small cell lung cancer in
first as well in second line-chemotherapy. Our results
are similar to the results of other studies which suggest
that gemcitabine with cisplatin or carboplatin is one of
the referential standards for treatment of advanced
non-small cell lung cancer. Although there are no stud-
ies that compared gemcitabine and docetaxel in sec-
ond-line chemotherapy, first results showed efficacy of
gemcitabine, alone or in combination, as acceptable
choice for second-line chemotherapy of advanced non-
-small cell lung cancer30,31. Our results confirm these
conclusions. Limitation of our study is that is retrospec-
tive and on relatively small number of patients. Pro-
spective studies have possibility for inclusion of more
patients which can be randomly chosen. The use of more
exact methods for diagnosing NSCLC will also contrib-
ute to better validation of chemotherapy results32.
R E F E R E N C E S
1. DETTERBECK, F. C., M. P. RIVERA, M. A. SOCINSKI: Diagno-
sis and treatment of lung cancer. (Saunders, Philadelphia, 2001). — 2.
BROKER, L. E., G. GIACCONE, Eur. J. Cancer, 38 (2002) 2346. — 3.
GANZ, P. A., R. A. FIGLIN, C. M. HASDEL, Cancer, 63 (1989) 1271. —
4. NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP,
Br. Med. J., 311 (1995) 899. — 5. CULLEN, M. H., L. J. BILLINGHAM,
C. M. WOODROFFE, A. D. CHETIYAWARDANA, N. H. GOWER, R.
JOSHI, D. R. FERRY, R. M. RUDD, S. G. SPIRO, J. E. COOK, C. TRASK,
E. BESSELL, C. K. CONNOLLY, J. TOBIAS, R. L. SOUHAMI, J. Clin.
Oncol.,17 (1999) 3188. — 6. SCHILLER, J. H., Oncology, 61 Suppl. 1
(2001) 3. — 7. RAMALINGAM, S., P. BELANI, Seminars in Oncology, 31
(2001) 68. — 8. LILENBAUM, R. C., J. HERDON, M. LIST, Proc. Am.
Soc. Clin. Oncol., 21 (2002) 1. — 9. SEDERHOLM, C., Proc. Am. Soc.
Clin. Oncol., 21 (2002) 291. — 10. SHEPARD, F. A., Expert. Rev. Anti-
cancer Ther., 3 (2003) 435. — 11. FOSSELA, F. V., T. LYNCH, F. A. SHE-
PERD, Lung cancer, 38 Suppl. 4 (2002) 5. — 12. HUANG, P., L. W.
CHUBB, G. B. GRINDEY, W. PLUNKETT, Cancer, 51 (1991) 6110. —
13. PETERS, G. J., V. T. W. RUIZ VA HAPEREN, A. M. BERBMAN,
Semin. Oncol. 2 (1995) 72. — 14. KAPLAN Z. L., P. MEIER, J. Am. Stat.
Assoc., 53 (1958) 457. — 15. CARDENAL, F., M. P. LOPEZ-CABRERIZO,
A. ANTON, V. ALBEROLA, B. MASSUTI, A. CARRATO, I. BARNETO,
M. LOMAS, M. GARCIA, P. LIANES, J. MONTALAR, C VADELL, J. L.
B. ^u~evi} et al.: Gemcitabine in Non-Small Cell Lung Cancer, Coll. Antropol. 29 (2005) 2: 583–588
587
GONZALES-LARRIBA, B. NGUYEN, A. ARTRAL, R. ROSELL, J. Clin.
Oncol., 17 (1999) 12. — 16. SCHILLER, J., D. HARRINGTON, C. P. BE-
LANI, C. LANGER, A. SANDLER, J. KROOK, J. ZHU, D. H. JOHN-
SON, N. Engl. J. Med., 346 (2002) 92. — 17. DANSON, S., M. R. MID-
DLETON, K. J. O´BYRNE, M. CLWMONS, M. RANSON, J. HASSA, H.
ANDERSON, P. A. BURT, C. FAIRVE-FIN, R. STOUT, I. DOWD, L.
ASHCROFT, C. BERESFORD, N. THATCHER, Cancer, 98 (2003) 542.
— 18. CRINO, L., G. SCAGLIOTTI, M. MARANGOLO, J. Clin. Oncol.,
15 (1997) 297. — 19. CHEN S. C. H., M. C. LIN, J. W. C. CHANG, S. W.
WANG, C. H. LEE, T. C. Y. TSAO, Jpn. J. Clin. Oncol., 30 (2000) 494. —
20. LE CHEVALIER, T., G. SCAGLIOTTI, R. NATALE, S. DANSON, R.
ROSELL, R. STAHEL, P. THOMAS, R. M. RUDD, J. VANSTEEKISTE,
N. THATCHER, C. MANEGOLD, J. L. PUJOL, N. VAN ZADWIJK, C.
GRIDELLI, J. P. VAN MEERBEECK, L. CRINO, A. BROWN. P. FITZ-
GERALD, M. ARISTIDES, J. F. SCHILLER, Lung Cancer, 47 (2005) 69.
— 21. SHEPHERD, F. A., F. V. FOSSELLA, T. LYNCH, J. P. ARMAND,
J. R. RIGAS, M. G. KRIS, Semin. Oncol., 29 Suppl. 2 (2001) 4. — 22.
WACHTERS, F. M., J. W. VAN PUTEN, H. M. BOEZEN, H. J. GROEN,
Lung Cancer, 45 (2004) 255. — 23. FERRIGNO, D., G. BUCCHERI, Lung
Cancer, 29 (2000) 91. — 24. CRINO, L., A. M. MOSCONI, G. SCAG-
LIOTTI, G. SELVAGGI, S. NOVELLO, M. RINALDI, M. DELLA GIULIA,
C. GRIDELLI, A. ROSSI, C. CALANDRI, F. DE MARINIS, M. NOSE-
DA, M. TONATO, J. Clin. Oncol., 17 (1999) 2081. — 25. GILLENWAT-
ER, H. H., M. TYNAN, S. NATOLI, M. J. SCHELL, M. A. SOCINSKI,
Cancer, 2 (2000) 133. — 26. VAN PUTEN, J. W., P. BAAS, H. COND-
RIGTON, H. B. KWA, M. MULLER, N. AARONSON, H. J. GROEN,
Lung Cancer, 33 (2001) 289. — 27. PECTASIDES, D., N. MYLONAKIS,
D. FARMAKIS, M. NIKOLAOU, M. KOUMPOU, I. KATSELIS, A. GAG-
LIA, V. KOSTOPOULOU, A. KARABELIS, C. KOSMAS, Anticancer.
Res., 23 (2003) 4205. — 28. CHEN, Y. M., R. P. PERNG, C. S. LEE, W. C.
LIN, C. M. TSAI, J. WANG-PENG, Am. J. Clin. Oncol., 26 (2003)567. —
29. NIHO, S., K. KUBOTA, H. OHMATSU, T. MATSUMOTO, R. KA-
KINUMA, Y. NISHIWAKI, Cancer Chemother. Pharmacol., 52 (2003)
19. — 30. CRINO, L., F. CAPPUZZO, Expert. Opin. Pharmacother., 3
(2002) 745. — 31. MANGELOD, C., Expert. Rev. Anticancer. Ther., 4
(2004) 345. — 32. PAVI^EVI], R., J. MILI^I], G. BUBANOVI], S.
[UPE, Coll. Antropol., 22(2) (1998) 629.
B. ^u~evi}
University Hospital for Lung Diseases »Jordanovac«, Jordanovac 104, 10000 Zagreb, Croatia
e-mail: branka.cucevic@zg.htnet.hr
GEMCITABINE U PRVOJ I DRUGOJ LINIJI KEMOTERAPIJE UZNAPREDOVALOG
NEMIKROCELULARNOG KARCINOMA PLU]A
S A @ E T A K
Cilj sudije je bila procjena u~inkovitosti gemcitabina u prvoj i drugoj liniji kemoterapije uznapredovalog nemi-
krocelularnog karcinoma plu}a (stadij III i IV). Razli~itim kemoterapijskim protokolima lije~eno je u prvoj liniji 120
bolesnika. Kod 59 bolesnika primjenjena je kombinacija gemcitabine/cisplatin (PG), kod 41 cisplatin/etoposide (PE) i
kod 20 mitomycin/ifosfamide/cisplatin (MIC). Od ~etrdeset bolesnika neuspje{no lije~enih kombinacijama PE i MIC u
prvoj liniji, njih 24 lije~eno je u drugoj liniji kombinacijom PG, a 16 bolesnika samo suportivnom terapijom (BSC). U
prvoj liniji kemoterapije PG protokol je pokazao bolje rezultate nego PE i MIC protokoli (srednje pre`ivljenje (MS) 10
u odnosu na 7 i 8.5 mjeseci). Stopa odgovora (RR) za PG u prvoj liniji je bila 46% a u drugoj liniji 21%. Dokazali smo
tako|er da je pre`ivljenje bolesnika lije~enih kombinacijom PG u drugoj liniji znatno bolje, nego onih koji su lje~eni
samo suportivnom terapijom (MS: 9 u odnosu na 5.5 mj.). Nuspojave kod bolesnika lije~enih kombinacijom PG su
prihvatljive. Ovaj je rad pokazao da je gemcitabine (u kombinaciji s cisplatinom) siguran i u~inkovit u prvoj i drugoj
liniji kemoterapije uznapredovalog nemikrocelularnog karcinoma plu}a.
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